

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp-Ropinirole	ReQuip	ropinirole HCl	0.25mg	FC tablet	02352338
Jamp Pharma Corporation	Jamp-Ropinirole	ReQuip	ropinirole HCl	1mg	FC tablet	02352346
Jamp Pharma Corporation	Jamp-Ropinirole	ReQuip	ropinirole HCl	2mg	FC tablet	02352354
Jamp Pharma Corporation	Jamp-Ropinirole	ReQuip	ropinirole HCl	5mg	FC tablet	02352362
Jamp Pharma Corporation	Jamp-Pravastatin	Pravachol	pravastatin sodium	10mg	tablet	02330954
Jamp Pharma Corporation	Jamp-Pravastatin	Pravachol	pravastatin sodium	20mg	tablet	02330962
Jamp Pharma Corporation	Jamp-Pravastatin	Pravachol	pravastatin sodium	40mg	tablet	02330970
Teva Canada Ltd.	Novo-Alfuzosin PR	Xatral	alfuzosin HCl	10mg	ER tablet	02314282

Updated: September 15, 2010